Form 8-K - Current report:
SEC Accession No. 0001193125-25-281498
Filing Date
2025-11-14
Accepted
2025-11-14 07:00:12
Documents
15
Period of Report
2025-11-13
Items
Item 2.02: Results of Operations and Financial Condition
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d26766d8k.htm   iXBRL 8-K 31344
2 EX-23.1 d26766dex231.htm EX-23.1 1748
3 EX-99.1 d26766dex991.htm EX-99.1 73030
4 EX-99.2 d26766dex992.htm EX-99.2 290465
  Complete submission text file 0001193125-25-281498.txt   582402

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA jbio-20251113.xsd EX-101.SCH 2846
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE jbio-20251113_lab.xml EX-101.LAB 19499
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE jbio-20251113_pre.xml EX-101.PRE 12153
18 EXTRACTED XBRL INSTANCE DOCUMENT d26766d8k_htm.xml XML 3938
Mailing Address 221 CRESCENT ST. BUILDING 23, SUITE 105 WALTHAM MA 02453
Business Address 221 CRESCENT ST. BUILDING 23, SUITE 105 WALTHAM MA 02453 (781) 312-3013
Jade Biosciences, Inc. (Filer) CIK: 0001798749 (see all company filings)

EIN.: 831377888 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40544 | Film No.: 251481093
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)